<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03305913</url>
  </required_header>
  <id_info>
    <org_study_id>0116-ASG</org_study_id>
    <secondary_id>2016-001968-11</secondary_id>
    <nct_id>NCT03305913</nct_id>
  </id_info>
  <brief_title>Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy</brief_title>
  <acronym>REMETY</acronym>
  <official_title>Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy: A Multicenter Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study&#xD;
      evaluating the safety and anti-tumor activity of TAS-102 administered in combination with&#xD;
      Regorafenib in patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine safety, feasibility and the recommended phase II dose&#xD;
      (RP2D) of a combination treatment consisting of TAS-102 and Regorafenib in subjects with mCRC&#xD;
      who have progressed after standard therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>According to the standard 3+3 dose finding strategy, a safety assessment will be performed after the test of each dose level (patient cohorts of n=3) and the frequency of DLTs determined. Based on the results the dose for the consecutive patient cohort will either be escalated (0/3 DLTs), repeated (1/3 DLTs) or deescalated (&gt;1/3 DLTs).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>2 months</time_frame>
    <description>Maximum Tolerated Dose (MTD) will be determined by recording dose limiting toxicities (DLT) occurring during the first 2 treatment cycles of each patient in each tested dose level. DLT will be identified by observing frequency and severity of specific adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) according to RECIST 1.1 criteria</measure>
    <time_frame>approx. 12 months</time_frame>
    <description>ORR is defined as the proportion of ALL Treated Subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the date of subject enrollment and the date of objectively documented progression. For subjects without documented progression, all available response designations will contribute to the BOR determination.&#xD;
ORR will be evaluated by reporting absolute and relative frequencies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>approx. 12 months</time_frame>
    <description>Progression free survival will be calculated from the date of subject enrollment until the date of confirmed PD or death from any cause. If no event is observed (e.g. lost to follow-up) PFS is censored at the time of last tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>approx. 12 months</time_frame>
    <description>Overall Survival will be calculated from the date of subject enrollment until the date of death from any cause. If no event is observed (e.g. lost to follow-up) OS is censored at the day of last subject contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>approx. 12 months</time_frame>
    <description>Incidence of AEs, SAEs, Treatment Emergent Adverse Events according to CTC 4.03</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pretreated Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS 102</intervention_name>
    <description>TAS-102 tablet</description>
    <arm_group_label>Dose Level -1a</arm_group_label>
    <arm_group_label>Dose Level -1b</arm_group_label>
    <arm_group_label>Dose Level -2a</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>Lonsurf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib tablet</description>
    <arm_group_label>Dose Level -1a</arm_group_label>
    <arm_group_label>Dose Level -1b</arm_group_label>
    <arm_group_label>Dose Level -2a</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent and any locally-required authorization (EU Data Privacy&#xD;
             Directive in the EU) obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations&#xD;
&#xD;
          2. Age ≥ 18 years at time of study entry&#xD;
&#xD;
          3. Histological or cytological documentation of adenocarcinoma of the colorectal region&#xD;
             (CRC)&#xD;
&#xD;
          4. Metastatic disease not amenable to surgical resection with curative intent&#xD;
&#xD;
          5. Study treatment must constitute 3rd-line treatment for metastatic disease. Prior&#xD;
             treatment lines must encompass at least one fluoropyrimidine-based chemotherapy, an&#xD;
             anti-VEGF and, in case of RAS wildtype tumors, an anti-EGFR treatment.&#xD;
&#xD;
          6. Patients treated with oxaliplatin in an adjuvant setting need to have progressed&#xD;
             during or within 6 months of completion of adjuvant therapy to be counted as prior&#xD;
             treatment line. Note: Neoadjuvant, perioperative or adjuvant regimens with progression&#xD;
             more than 6 months after completion are not considered as prior treatment line for&#xD;
             metastatic disease.&#xD;
&#xD;
          7. Measurable disease, defined as at least one unidimensional measurable lesion on a CT&#xD;
             scan as defined by RECIST 1.1&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status &lt;2 and life expectancy of&#xD;
             at least 3 months&#xD;
&#xD;
          9. Adequate bone marrow, renal, and hepatic function, as evidenced by the following&#xD;
             within 7 days prior to study treatment initiation:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1,500/mm3&#xD;
&#xD;
               -  Platelets ≥100,000/mm3&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) ≥30 mL/min/1.73m2&#xD;
&#xD;
               -  AST and ALT ≤2.5 x ULN (≤5.0 × ULN for patients with liver involvement of their&#xD;
                  cancer)&#xD;
&#xD;
               -  Bilirubin ≤1.5 X ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN with liver involvement of their cancer)&#xD;
&#xD;
               -  Amylase and lipase ≤1.5 x ULN&#xD;
&#xD;
               -  Spot urine must not show 1+ or more protein in urine or the patient will require&#xD;
                  a repeat urine analysis. If repeated urinalysis shows 1+ protein or more, a&#xD;
                  24-hour urine collection will be required and must show total protein excretion&#xD;
                  &lt;1000 mg/24 hours&#xD;
&#xD;
               -  INR/PTT ≤1.5 x ULN (Patients who are therapeutically treated with an agent such&#xD;
                  as warfarin or heparin will be allowed to participate provided that no prior&#xD;
                  evidence of underlying abnormality in coagulation parameters exists. Close&#xD;
                  monitoring of at least weekly evaluations will be performed until INR/PTT is&#xD;
                  stable based on a measurement that is pre-dose as defined by the local standard&#xD;
                  of care.)&#xD;
&#xD;
         10. Women of childbearing potential and male subjects must agree to use adequate&#xD;
             contraception for the duration of study participation and up to 6 months following&#xD;
             completion of therapy. Females of childbearing potential who are sexually active with&#xD;
             a non-sterilized male partner must use 2 methods of effective contraception from&#xD;
             screening, and must agree to continue using such precautions for 6 months after the&#xD;
             final dose of investigational product.&#xD;
&#xD;
         11. Female subjects must either be of non-reproductive potential (ie, post-menopausal by&#xD;
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;&#xD;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of&#xD;
             bilateral oophorectomy) or must have a pregnancy test performed at a maximum of 7 days&#xD;
             before start of treatment, and a negative result must be documented before start of&#xD;
             treatment.&#xD;
&#xD;
         12. In the assessment of the investigator, patient is able to comply with study&#xD;
             requirements.&#xD;
&#xD;
         13. Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with Regorafenib, or any other tyrosine kinase inhibitor for the&#xD;
             treatment of malignancy&#xD;
&#xD;
          2. Prior treatment with TAS-102&#xD;
&#xD;
          3. Previous or concurrent cancer that is distinct in primary site or histology from&#xD;
             colorectal cancer within 5 years prior to study inclusion EXCEPT for curatively&#xD;
             treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder&#xD;
             tumors [Ta (Non invasive tumor), Tis (Carcinoma in situ) and T1 (Tumor invades lamina&#xD;
             propria)].&#xD;
&#xD;
          4. Known history of/or concomitant malignancy other than mCRC likely to affect life&#xD;
             expectancy in the judgment of the investigator&#xD;
&#xD;
          5. History of Gilbert's syndrome&#xD;
&#xD;
          6. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             and last chemotherapy &lt;21 days prior to first dose of treatment&#xD;
&#xD;
          7. Radiotherapy within 4 weeks prior to first dose of treatment&#xD;
&#xD;
          8. Active cardiac disease including any of the following:&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association NYHA) ≥Class 2&#xD;
&#xD;
               -  Unstable angina (angina symptoms at rest), new-onset angina (within the last 3&#xD;
                  months).&#xD;
&#xD;
               -  Myocardial infarction less than 6 months before start of Day 1 of treatment.&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin&#xD;
                  are permitted)&#xD;
&#xD;
               -  Uncontrolled hypertension. (Systolic blood pressure &gt;140 mmHg or diastolic&#xD;
                  pressure &gt;90 mmHg despite optimal medical management)&#xD;
&#xD;
          9. Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within 6 months before start of treatment&#xD;
&#xD;
         10. Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         11. Chronic hepatitis B or C infection (If hepatitis status can not be obtained from&#xD;
             medical records re-testing is required.)&#xD;
&#xD;
         12. Patients with seizure disorder requiring medication&#xD;
&#xD;
         13. Symptomatic metastatic brain or meningeal tumors unless the patient is &gt;6 months from&#xD;
             definitive therapy, has a negative imaging study within 4 weeks prior to treatment&#xD;
             initiation, and is clinically stable with respect to the tumor at the time of study&#xD;
             entry. Also, the patient must not be undergoing acute steroid therapy or taper&#xD;
             (chronic steroid therapy is acceptable, provided that the dose is stable for one month&#xD;
             prior to and following screening radiographic studies).&#xD;
&#xD;
         14. History of organ allograft&#xD;
&#xD;
         15. Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ Grade 3&#xD;
             (CTCAE v. 4.0) within 4 weeks prior to the start of study treatment.&#xD;
&#xD;
         16. Non-healing wound, ulcer or bone fracture&#xD;
&#xD;
         17. Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
         18. Dehydration according to CTCAE v. 4.03 Grade &gt;1&#xD;
&#xD;
         19. Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
         20. Known hypersensitivity to any of the study drugs, study drug classes, or any&#xD;
             constituent of the products&#xD;
&#xD;
         21. Known dihydropyrimidine dehydrogenase (DPD) deficiency or treatment with DPD&#xD;
             inhibitors, including sorivudine or its chemically related analogues such as brivudine&#xD;
             within 4 weeks prior to the start of study treatment.&#xD;
&#xD;
         22. Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent.&#xD;
&#xD;
         23. Inability to swallow oral medications&#xD;
&#xD;
         24. Any malabsorption condition&#xD;
&#xD;
         25. Unresolved toxicity higher than Grade 1 CTCAE v. 4.03 attributed to any prior&#xD;
             therapy/procedure excluding alopecia, anemia and oxaliplatin-induced neurotoxicity&#xD;
             (which must be ≤Grade 2) or ongoing infection &gt;Grade 2.&#xD;
&#xD;
         26. Patients unable or unwilling to discontinue (and substitute if necessary) use of&#xD;
             prohibited drugs for at least 2 weeks prior to Day 1 of treatment initiation.&#xD;
&#xD;
         27. Female subjects who are pregnant, breast-feeding or intent to become pregnant&#xD;
&#xD;
         28. Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results&#xD;
&#xD;
         29. Participation in another clinical study with an investigational product during the&#xD;
             last 30 days before inclusion&#xD;
&#xD;
         30. Previous enrollment in the present study (does not include screening failure).&#xD;
&#xD;
         31. Involvement in the planning and/or conduct of the study (applies to Bayer staff and/or&#xD;
             staff of sponsor and/or staff of the CRO and study site)&#xD;
&#xD;
         32. Patient who might be interconnected with or dependent on the sponsor, site or the&#xD;
             investigator Patient who has been incarcerated or involuntarily institutionalized by&#xD;
             court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Möhler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik, Langenbeckstraße 1, 55131 Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03305913
org study id: 0116-ASG
secondary id: 2016-001968-11
nct id: NCT03305913
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study
      evaluating the safety and anti-tumor activity of TAS-102 administered in combination with
      Regorafenib in patients with metastatic colorectal cancer.
The primary objective is to determine safety, feasibility and the recommended phase II dose
      (RP2D) of a combination treatment consisting of TAS-102 and Regorafenib in subjects with mCRC
      who have progressed after standard therapy.
allocation: Non-Randomized
intervention model: Sequential Assignment
intervention model description: According to the standard 3+3 dose finding strategy, a safety assessment will be performed after the test of each dose level (patient cohorts of n=3) and the frequency of DLTs determined. Based on the results the dose for the consecutive patient cohort will either be escalated (0/3 DLTs), repeated (1/3 DLTs) or deescalated (>1/3 DLTs).
primary purpose: Treatment
masking: None (Open Label)
measure: Maximum Tolerated Dose (MTD)
time frame: 2 months
description: Maximum Tolerated Dose (MTD) will be determined by recording dose limiting toxicities (DLT) occurring during the first 2 treatment cycles of each patient in each tested dose level. DLT will be identified by observing frequency and severity of specific adverse events.
measure: Overall Response Rate (ORR) according to RECIST 1.1 criteria
time frame: approx. 12 months
description: ORR is defined as the proportion of ALL Treated Subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the date of subject enrollment and the date of objectively documented progression. For subjects without documented progression, all available response designations will contribute to the BOR determination.
ORR will be evaluated by reporting absolute and relative frequencies.
measure: Progression-free survival (PFS)
time frame: approx. 12 months
description: Progression free survival will be calculated from the date of subject enrollment until the date of confirmed PD or death from any cause. If no event is observed (e.g. lost to follow-up) PFS is censored at the time of last tumor assessment.
measure: Overall survival (OS)
time frame: approx. 12 months
description: Overall Survival will be calculated from the date of subject enrollment until the date of death from any cause. If no event is observed (e.g. lost to follow-up) OS is censored at the day of last subject contact.
measure: Incidence of Treatment-Emergent Adverse Events
time frame: approx. 12 months
description: Incidence of AEs, SAEs, Treatment Emergent Adverse Events according to CTC 4.03
arm group label: Dose Level 1
arm group type: Experimental
description: TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
arm group label: Dose Level 2
arm group type: Experimental
description: TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
arm group label: Dose Level 3
arm group type: Experimental
description: TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
arm group label: Dose Level -1a
arm group type: Experimental
description: TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
arm group label: Dose Level -1b
arm group type: Experimental
description: TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
arm group label: Dose Level -2a
arm group type: Experimental
description: TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
intervention type: Drug
intervention name: TAS 102
description: TAS-102 tablet
arm group label: Dose Level -1a
arm group label: Dose Level -1b
arm group label: Dose Level -2a
arm group label: Dose Level 1
arm group label: Dose Level 2
arm group label: Dose Level 3
other name: Lonsurf
intervention type: Drug
intervention name: Regorafenib
description: Regorafenib tablet
arm group label: Dose Level -1a
arm group label: Dose Level -1b
arm group label: Dose Level -2a
arm group label: Dose Level 1
arm group label: Dose Level 2
arm group label: Dose Level 3
other name: Stivarga
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Markus Möhler, Prof. Dr.
role: Principal Investigator
affiliation: Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik, Langenbeckstraße 1, 55131 Mainz
facility: 
country: Germany
responsible party type: Sponsor
mesh term: Colorectal Neoplasms
sharing ipd: No